Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
NOT YET RECRUITING
NCT07483801
PHASE4

DECODE - Haemodynamic Effects Of Semaglutide and Tirzepatide - a Series of Pilot Studies

Sponsor: Cambridge University Hospitals NHS Foundation Trust

View on ClinicalTrials.gov

Summary

What is the research question? Semaglutide and tirzepatide cause weight loss and blood pressure reduction. However, weight loss only partially explains the blood pressure reduction. Based on previous studies, there might be direct effects in the cardiovascular system. In forearm blood flow studies, semaglutide and tirzepatide will be infused into the brachial artery to investigate their effects on the function of blood vessels. In systemic studies, semaglutide and tirzepatide will be infused into systemic circulation to investigate their effects on heart and blood vessels. There are three different populations being looked at for this study: participants with normal weight and normal blood pressure, participants with obesity and normal blood pressure, and participants with obesity and high blood pressure. There are six sub-studies each with different visit schedules. The minimum participant study duration (including follow-up phone call) would be 2 days, while the maximum participant study duration would be approximately 2 - 2.5 months. The overall study duration is expected to be approximately 18 months.

Key Details

Gender

All

Age Range

18 Years - 50 Years

Study Type

INTERVENTIONAL

Enrollment

112

Start Date

2026-03

Completion Date

2028-04

Last Updated

2026-03-19

Healthy Volunteers

Yes

Interventions

DRUG

semaglutide

Semaglutide: GLP-1 analogue

DRUG

Tirzepatide

Tirzepatide: dual GIP/GLP-1 receptor agonist

Locations (1)

Addenbrooke's Hospital

Cambridge, Cambridgeshire, United Kingdom